Stratified Medicine to Optimise the Treatment of Patients with Hepatitis C Virus Infection

  • no-js


STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.


Professor Ellie Barnes (STOP-HCV lead) talks to the Oxford Centre for Personalised Medicine about the project.

STOP-HCV Partners

The STOP-HCV consortium is formed of 21 partners representing academia, industry and the Hepatitis C Trust.

See partners >>


Read more about the science we've published.

Latest News

STOP-HCV - precision medicine for hepatitis C treatment - presented at the NHS Scotland 2016 annual conference -  view Dr John McLauchlan's  slides.

STOP-HCV Cirrhosis Study reaches 1200 patient recruitment target. 1264 patients (recruited from over 30 hospital sites) are enrolled in the STOP-HCV Cirrhosis Study. 

STOP-HCV Consortium publishes findings from its HCV next generation sequencing methods comparison exercise - available online at Journal of Clinical Microbiology.

Viral hepatitis is now the 7th leading cause of death worldwide - findings from the Global Burden of  Disease study 2013, published by the Lancet online 6 July 2016.

How to prioritise high-cost HCV treatment? - STOP-HCV investigator Natasha Martin, and others, address this question in an article in the Journal of Hepatology. 

STOP-HCV-1 - STOP-HCV investigator, Dr Graham Cooke, has secured funding from the NIHR Efficacy and Mechanism Evaluation programme to undertake a clinical study (STOP-HCV-1) to look at stratification within short-course, all-oral direct-acting antiviral HCV treatment regimes, for Gt1 HCV infected patients with mild liver disease.